Author

Lishi Xie

University of ChicagoORCID 0000-0003-2376-6685Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Approach:statistical model· 1

Frequent Co-Authors

Xiufen CheniD· 2 shared Alan B CooperiD· 1 shared Ali ElSheikh· 1 shared Duy-Thuc NguyeniD· 1 shared Erting TangiD· 1 shared Guoshuai CaoiD· 1 shared Han Liu· 1 shared Hanna A. RuiziD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Xiufen ChenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintOct 21, 2026

Harnessing the PRDM1-PGC1A axis to enhance CAR T cell efficacy

Sidney YY Wang, Xiufen Chen, Xubin Li…·Jutin Kline

This study identifies the PRDM1-PGC1A axis as a key regulator of CAR T cell function, showing that inhibiting PRDM1 or activating PGC1A improves CAR T cell efficacy in multiple tumor models.

DOI 10.64898/2026.10.15.759372

humanstatistical model

𝕏 PostBluesky

ImmunologyCancer Immunology ResearchPeer-reviewedMay 8, 2026

Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy

Erting Tang, Yifei Hu, Guoshuai Cao…·Jun Huang

This study shows that low-strength type I interferon signaling enhances CAR T-cell efficacy against B-cell lymphoma and leukemia without causing in vivo toxicity.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky